Inhaled insulin has been one of those biotech ideas that have seemed better on paper than in practice. Huge investments have been made to carry these products through challenging development only to end in market flops. Aerami Therapeutics, a company founded by one of the pioneers in the field, is advancing its version of inhaled insulin and building a pipeline of other inhaled biologics behind it We spoke to Anne Whitaker, CEO of Aerami, about its pursuit of inhaled insulin, why she believes the company will be able to avoid the pitfalls others have faced, and the case for delivering insulin and other biologics through the lung with its technology.